Insulin Regulation of Lipolysis and Lipolysis Proteins

Launched by MAYO CLINIC · Mar 5, 2019

Keywords

ClinConnect Summary

This clinical trial is studying how insulin affects the way our bodies break down fat, particularly in people who have obesity focused in the upper body. The researchers want to understand why insulin sometimes doesn’t work as well in these individuals and how a medication called pioglitazone, often used to treat type 2 diabetes, can help improve this process. By looking at specific proteins in fat cells, the team hopes to uncover important information that could lead to better treatments for obesity-related issues.

The trial is open to men and women aged 18 to 55, including those who are non-obese or mildly obese. To participate, individuals need to have a body mass index (BMI) between 18-25 if non-obese, or a BMI between 30-38 if obese. Participants can expect to undergo tests and assessments to help researchers gather valuable data. It’s important to note that individuals with certain heart conditions or allergic reactions to pioglitazone cannot participate in this study. If you or someone you know fits the eligibility criteria and is interested, this trial could be an opportunity to contribute to important research on obesity and insulin regulation.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men and Women between the ages of 18 and 55.
• • Women will be premenopausal
• • Non obese adults BMI between 18-25
• • Obese BMI 30-38
• Exclusion Criteria, Pioglitazone package insert of contraindications for use:
• • Initiation in patients with established New York Heart Associations (NYHA) class III or IV Heart failure.
• • Use in patients with known hypersensitivity to pioglitazone or any other component of ACTOSE.